CN115969855A

CN115969855A - Application of APY29 in preparation of RSK4 kinase inhibitor

Info

Publication number: CN115969855A
Application number: CN202211618395.2A
Authority: CN
Inventors: 马静; 柴佳; 杨艳茹; 范林妮; 王凯靖; 刘一雄; 彭阳
Original assignee: Air Force Medical University of PLA
Current assignee: Air Force Medical University of PLA
Priority date: 2022-12-15
Filing date: 2022-12-15
Publication date: 2023-04-18
Anticipated expiration: 2042-12-15
Also published as: CN115969855B

Abstract

The invention belongs to the field of tumor drug research, and particularly relates to application of APY29 in preparation of an RSK4 kinase inhibitor. Test results show that APY29 can effectively inhibit the phosphorylation of RSK4 and the activation of RSK 4. The in vivo test result proves that APY29 can inhibit the proliferation and growth of renal cancer cells and the invasion and migration of the renal cancer cells. APY29 and sunitinib are used together, and can also obviously reduce angiogenesis of renal clear cell carcinoma.

Description

Application of APY29 in preparation of RSK4 kinase inhibitor

Technical Field

The invention belongs to the field of tumor drug research, and particularly relates to application of APY29 in preparation of an RSK4 kinase inhibitor.

Background

Renal Cell Carcinoma (RCC) is a common malignant tumor of the urinary system, originates in renal tubular epithelial cells, accounts for about 80-90% of the malignant tumor of the kidney, has various tissue types, is mainly renal clear cell renal cell carcinoma (ccRCC), and has a histological characteristic of being rich in blood vessels. Angiogenesis in renal cell carcinoma is closely related to the development, progression and treatment of tumors. At present, the treatment mode of RCC is mainly surgical excision, and for metastatic or unresectable RCC, the first-line treatment is to use tyrosine kinase inhibitor sunitinib and the like aiming at VEGF/VEGFR (vascular endothelial growth factor/vascular endothelial growth factor receptor) related to angiogenesis. However, the targeted drugs have many adverse reactions, about 70% of patients have hypertension or adverse reactions of hypertension development, and generally have drug resistance in about one year. Therefore, the research and the research of related strategies for preventing and treating RCC angiogenesis have important clinical significance, and can provide new theoretical basis and effective supplement for the targeted therapy of the RCC angiogenesis.

RSK4 is one of ribosome S6 protein kinase (RSK) family members, is coded by 746 amino acids, is used as a downstream molecule of a MAPK pathway, has important functions in the processes of cell proliferation, survival, cycle progression and the like, and also has important cancer promotion functions in the occurrence, development, invasion and metastasis of tumors such as esophageal cancer, endometrial cancer and breast cancer. Therefore, it is important to explore the inhibitors specific to the RSK4 kinase and provide a new therapeutic approach for patients with advanced renal cell carcinoma.

Disclosure of Invention

In view of the above technical problems, the present invention provides the following technical solutions:

in a first aspect of the invention, the invention provides an application of APY29 in preparing an RSK4 kinase inhibitor.

Preferably, the APY29 is used for preparing an inhibitor of the phosphorylation of ribosomal protein S6, a downstream substrate of RSK 4.

In a second aspect of the invention, the invention provides an application of the APY29 in preparing a medicament for treating/preventing diseases related to RSK4 kinase.

Preferably, the RSK4 kinase-associated disease is renal cancer.

Preferably, the renal cancer is renal clear cell carcinoma.

Preferably, the APY29 is used for preparing a proliferation inhibitor of renal clear cell carcinoma.

Preferably, the APY29 is used for preparing a blocker of invasion and migration of renal clear cell carcinoma.

In a third aspect of the invention, a medicament for treating/preventing a disease associated with RSK4 kinase is provided, which comprises the APY29.

Preferably, the medicament comprises sunitinib.

In a fourth aspect of the invention, the invention provides a use of the medicament in the preparation of a medicament for inhibiting abnormally active angiogenesis caused by renal clear cell carcinoma.

Compared with the prior art, the invention has the beneficial effects that:

the invention provides an application of APY29 in preparing an RSK4 kinase inhibitor. Test results show that APY29 can effectively inhibit the phosphorylation of RSK4 and the activation of RSK4, and the inhibition rate of APY29 on RSK4 kinase is 98.4%. The in vivo test result proves that APY29 can inhibit the proliferation and growth of renal cancer cells and the invasion and migration of the renal cancer cells. APY29 in combination with sunitinib also significantly reduced the abnormally active angiogenesis caused by renal clear cell carcinoma.

Drawings

FIG. 1 shows the inhibitory effect of APY29 on the RSK4 enzyme at various concentrations;

FIG. 2 is a Westernblot for detecting the effect of different concentrations of APY29 on the phosphorylation level of a substrate downstream of RSK 4;

FIG. 3 is a graph of the effect of various groups on cell ACHN cell proliferation;

fig. 4 is IC50=0.6233 μ M of APY29 in ACHN cells;

FIG. 5 is a diagram of the effect of Transwell assay APY29 on ACHN cell invasion; A. transwell experiments with APY29 on ACHN cell invasion; B. statistical data of Transwell experiments;

FIG. 6 is the effect of APY29 on ACHN cells following knockdown of RSK 4; A. after the RSK4 is knocked down, the invasion and migration capacity of the ACHN is weakened; B. statistical data of invasion migration experiments;

FIG. 7 is a graph of the inhibition of tumor growth in mice by groups;

FIG. 8 is the effect of sunitinib alone and APY29 in combination on HUVEC cell tubulation;

FIG. 9 is a statistical data showing the effect of sunitinib alone and APY29 in combination on the number of tubes formed by HUVEC cells.

Detailed Description

For a further understanding of the invention, reference will now be made to the preferred embodiments of the invention by way of example, and it is to be understood that the description is intended to further illustrate features and advantages of the invention, and not to limit the scope of the claims. Those skilled in the art can modify the process parameters appropriately in view of the disclosure herein. It is specifically noted that all such substitutions and modifications will be apparent to those skilled in the art and are intended to be included within the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention. While the following terms are believed to be well understood by those of ordinary skill in the art, the following definitions are set forth to aid in the description of the presently disclosed subject matter.

As used herein, the term "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional unrecited elements or method steps. "comprising" is a term of art used in claim language and means that the recited elements are present but that other elements may be added and still form a structure or method within the scope of the recited claims.

The CAS number of the APY29 used by the invention is 1216665-49-4, and the structure is shown as the formula I:

example 1

Inhibition of the RSK4 enzyme by APY29

1. Experimental methods

In the experiment, the ADP-Glo method is used for detecting the action of the compound APY29 to be detected on RSK4 enzyme.

The initial concentration of the compound to be tested is 10 mu M, and the compound is diluted by 5 times of gradient to obtain 6 compound APY29 solutions with different concentrations.

The specific operation process is as follows:

(1) The RSK4 enzyme, RSK Substrate, kinase buffer III (5 Xbuffer), dithiothreitol (DTT, 0.1M) and ATP (10 mM) were thawed on ice and the above reagents were required to be kept on ice throughout the experiment.

(2) Preparing 5 Xkinase buffer III into 1 Xbuffer by using deionized water, and adding DTT into the 1 Xbuffer, wherein the concentration of DTT in the 1 Xbuffer is 50 mu M;

(3) Adding 1 mul/hole 5 Xcompound APY29 to be tested into a white microporous plate, and centrifuging the microporous plate on a centrifuge at 1000r/min for 1 minute;

positive control wells (pos. Ctrl): 1 μ l/well compound dilution solvent;

blank control wells (Blank): 1 μ l/well 1 Xbuffer.

(4) After the RSK4 enzyme is completely thawed, diluting the RSK4 enzyme to 1 ng/mu l by using 1 multiplied kinase buffer solution III, taking 2 mu l/hole and adding the 2 mu l/hole into a white micropore plate, wherein the enzyme amount of the RSK4 in each hole is 2ng; add 2. Mu.l/well 1 Xbuffer to the blank control well; the step is carried out on ice, and after the step is finished, the microporous plate is centrifuged for 1 minute on a centrifuge at 1000 r/min;

(5) Preparing RSK Substrate/ATP mixed solution:

RSK Substrate/ATP mixture: mu.l of RSK Substrate (1 mg/ml) was added to 3.25. Mu.l of 5mM ATP and 127. Mu.l of 2 Xbuffer (note that this was a dilution in proportion), at which point the mixture had an ATP concentration of 62.5. Mu.M and an RSK Substrate concentration of 0.5mg/ml; please carry out this step on ice;

(6) Taking 2 mul/hole RSK Substrate/ATP mixed solution into a white microplate, wherein the concentration of RSK Substrate is 0.2mg/ml and the concentration of ATP is 25 mul, and centrifuging the microplate for 1 minute at 1000r/min after the addition;

(7) After the centrifugation is finished, the microporous plate is pasted with a film, the film is tightly pasted, and the incubation is carried out for 1 hour at the temperature of 25 ℃;

(8) The ADP-GloTM reagent and the kinase assay related reagents required in the Promega kit were equilibrated to room temperature and the kinase assay buffer and kinase assay substrate were mixed for use according to the instructions.

(9) After finishing incubation, adding 5 mu l/hole ADP-GloTM reagent into a white microporous plate, centrifuging the microporous plate for 1 minute at 1000 revolutions, and incubating for 40 minutes at 25 ℃;

(10) After the incubation is finished, adding 10 mul/hole of the Kinase Detection mixed solution into a microporous plate, centrifuging the microporous plate at 1000r/min for 1 minute, and incubating for 30 minutes at 25 ℃;

(11) After the incubation is finished, performing chemiluminescence detection on a plate reader, and reading a luminescence value (RLU);

(12) Calculation of enzyme inhibition:

enzyme inhibition (%) =100- (sample luminescence value-blank luminescence value)/(positive luminescence value-blank luminescence value) × 100%.

2. Results of the experiment

As shown in FIG. 1, the inhibitory effect of APY29 on RSK4 enzyme is enhanced with the increase of the concentration of APY29. Curve fitting was performed using GraphPad software to give an IC50 value of 55.1nM. The compound APY29 can effectively inhibit the phosphorylation of RSK4 and the activation of RSK4, and is a effective RSK4 inhibitor.

Example 2

Effect of APY29 on phosphorylation levels of downstream substrates of RSK4

1. Experimental methods

In the experiment, different concentrations of APY29 are adopted to stimulate a renal cancer cell line, and Westernblot is used for detecting the influence of the phosphorylation level of an RSK4 downstream substrate. The specific operation process is as follows:

(1) Protein extraction, using kang as a century RIPA lysate. The cell culture bottle is placed on ice for cracking for 20min, shaken back and forth, and blown and beaten by a gun head. The cells were scraped off with a cell scraper, transferred to an EP tube and centrifuged at 4 ℃. Protein quantification can be performed by pipetting 10-20. Mu.l. Adding loading buffer (prepared from 100 μ l RIPA lysate (strong), 1 μ l phosphatase inhibitor and 1 μ l protein inhibitor, all from Kangji reagent Co., ltd.), boiling for 5min, centrifuging at 12000rpm for 5min, and storing in ultra-low temperature refrigerator. Tissue protein extraction: grinding with liquid nitrogen, thawing, transferring into EP tube, cracking on ice for 20min, and centrifuging at 4 deg.C.

(2) Protein quantification was performed using a kang century BCA quantification kit. Making two multiple holes for each sample, taking the average value to make a standard curve and calculating the concentration of the sample.

(3) Protein electrophoresis, using Kangji century SDS-PAGE gel to prepare the kit. The concentration of the separation gel is 8 percent, and the concentration of the concentrated gel is 5 percent. The separation glue is 1.5cm away from the upper edge of the front glass plate, and water injection and glue sealing are performed. The water-sealed liquid is sucked dry by filter paper, the concentrated glue is poured, and a comb is inserted. The voltage is constant at 100V for 1 hour and 30min until bromophenol blue comes out, and the electrophoresis is stopped.

(4) And (3) transferring the membrane, namely soaking the glue, the filter paper and the sponge pad in a pre-cooled membrane transferring buffer solution with the temperature of 4 ℃ for balancing for 10min, soaking the PVDF membrane in methanol for 5min, fully wetting, and transferring the PVDF membrane to the membrane transferring buffer solution for soaking for 10min. Installing a film rotating clamp sequence: black plate, sponge, 3 layers of filter paper, glue, film, 3 layers of filter paper, sponge and white plate. Air bubbles need to be removed in each step, and the membrane is placed at one time. The film was transferred for 100min at a constant flow of 300mA in an ice bath.

(5) And sealing by using a 5% skimmed milk powder shaking table at room temperature for 1h. Rinse 10min × 3 times with TBST.

(6) And (3) performing primary antibody incubation, wherein the contact surface of the membrane and the glue is always upward during antibody incubation, and performing shaking table incubation at 4 ℃ overnight. The next day was rinsed with TBST.

(7) And (4) incubating the secondary antibody at room temperature for 1h. Rinse with TBST.

(8) Luminescence, using Kangji-century chemiluminescence detection kit, and scanning detection results with a chemiluminescence imager.

(9) And (4) performing semi-quantitative gray scale analysis on the image by using Photoshop software, and calculating the relative expression quantity of the protein.

2. Results of the experiment

As shown in FIG. 2, when 1uM and 10uMAPY29 are used for stimulating the renal cancer cell lines respectively, APY29 with different concentrations can inhibit the downstream substrate phosphorylation of RSK4 and down-regulate the expression of P-RPS6 (S235/S236) through Westernblot detection.

Example 3

Effect of APY29 on renal cancer cells

1. Experimental method

In the experiment, 1uM and 10uMAPY29 are adopted to stimulate a renal cancer cell line (ACHN), CCK8 is used for detecting the influence of APY29 on the proliferation of renal cancer cells, and Transwell is used for detecting the influence of APY29 on the migration of renal cancer cells, and BI-D1870 is used as a positive control and no drug is added as a Blank control (Blank).

1.1, CCK8 detection steps:

the cell proliferation is completed by using a CCK-8 cell proliferation kit of Shanghai Tao Shu Biotech Co. The specific operation process is as follows:

(1) The 96-well plate was seeded with cell suspension at 100. Mu.L per well and 2,000 cells per well.

(2) Culturing or administering medicine according to experiment requirement, and treating for appropriate time.

(3) Add 10. Mu.L of CCK-8 solution to each well and incubate at 37 ℃.

(4) The microplate reader selects the wavelength of 450nm to determine the absorbance value. Growth curves were plotted as time and absorbance values.

1.2, a Transwell migration experiment step:

(1) The cells are digested. Washed once with PBS, resuspended in serum-free medium and adjusted to a cell density of 5X 10 ⁵ /ml。

(2) 500ul of medium containing 10% fetal bovine serum was added to the lower chamber of the 24-well plate. 200 μ l of cell suspension was added to the chamber to note that there were no air bubbles in the chamber and the underlying medium.

(3) Culturing for 16-24h.

(4) The chamber medium was aspirated, the chamber cells were fixed with anhydrous methanol for 15min, and rinsed with PBS.

(5) Seven colors: the Gu Msa staining solution was added to the 24-well plate, the membrane was immersed in the staining solution and stained for 20min, and washed with PBS.

(6) The cells in the inner layer of the membrane were carefully wiped off with a cotton swab and the membrane was air-dried.

(7) Take pictures under microscope, count 5 high power fields, and take the average value.

2 results of the experiment

Compared with a blank control, both APY29 and BI-D1870 can inhibit the proliferation of ACHN cells, and the inhibition effect of APY29 is stronger under the same drug concentration. As can be seen from fig. 3, APY29 can significantly inhibit the proliferation activity of ACHN tumor cells. As can be seen from FIG. 4, the IC50 of APY29 is 0.62. Mu.M. As can be seen in fig. 5, APY29 inhibited RCC invasion and migration in vitro. As can be seen from FIG. 6, the inhibition of APY29 was reduced after knocking down RSK 4.

Example 4

APY29 inhibits the growth of renal cancer cells in vivo

1. Experimental methods

Nude mouse tumorigenesis experiment:

(1) 4-6 weeks old female BALB/c nude mice were subjected to nude mouse tumorigenesis experiments, 5 nude mice per group, and 1X 10 mice per mouse were injected subcutaneously ⁶ Each ESCC cell was dissolved in 200. Mu.l of sterile PBS.

(2) When the tumor volume reaches 150mm ³ And grouping and carrying out different processing. APY29 administration is intraperitoneally injected at 15mg/kg or 30mg/kg daily (drug dissolved concentration: 5mg/ml, solvent: 2% DMSO +2% Tween-80+30% PEG300+ sterile water), with BI-D1870 as a positive control.

(3) The observation time of the nude mouse tumorigenesis experiment lasts for 20 days, and the mice are timely treated when the mice are infected and the conditions are poor. During which tumor volume measurements were taken every 3 to 5 days.

(4) Mice were sacrificed at the end of the experimental time, subcutaneous tumors were removed, photographed, weighed, and counted.

2. Results of the experiment

APY29 showed a stronger inhibition of tumor growth than the negative control and the spectral inhibitor of RSK4, BI-D1870, see FIG. 7.

Example 5

APY29 synergistic treatment of renal cell carcinoma angiogenesis with sunitinib

1. Experimental methods

Sunitinib (2 mu m), sunitinib (2 mu m) and APY29 (10 mu m) are adopted to respectively stimulate HUVEC (human umbilical vein endothelial cells) cells co-cultured with ACHN, and the influence of different drugs on HUVEC cell tube formation is detected.

Tube forming experiment:

A. the huvec cells are prepared for digestion after reaching 80% confluence degree, generally the cell state after overnight culture is better, the cells are collected for counting, and the concentration of the cells is adjusted by gradient dilution according to requirements, so that the cell state is ensured to be intact.

B. Adding 200ul HUVEC cell suspension into a 24-well plate, wherein the concentration is about 12-20 ten thousand cells, and making multiple wells; after the cells are added, the culture plate should not be moved, and the cells are placed in an incubator at 37 ℃ for about 4 hours to observe whether blood vessels are formed.

C. Typically, tube formation will begin to slowly shrink apoptosis after 15 hours.

D. And analyzing results and acquiring pictures. Fluorescent staining can be carried out after fixation according to requirements.

2. Results of the experiment

As can be seen from fig. 8 to 9, the combination significantly reduced the abnormal active angiogenesis caused by renal clear cancer. The sunitinib and APY29 are proved to have a synergistic effect, and the result provides a new idea for treating the kidney cancer.

The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such modifications are intended to be included in the scope of the present invention.

Claims

1. Use of APY29 in preparing RSK4 kinase inhibitor is provided.

2. The use according to claim 1, wherein APY29 is used for the preparation of an inhibitor of the phosphorylation of ribosomal protein S6, the downstream substrate of RSK 4.

3. The application of the APY29 in preparing medicines for treating/preventing RSK4 kinase related diseases.

4. The use according to claim 3, wherein the RSK4 kinase-associated disease is renal cancer.

5. Use according to claim 4, characterized in that the renal cancer is renal clear cell carcinoma.

6. The use according to claim 5, wherein APY29 is used for the preparation of a proliferation inhibitor of renal clear cell carcinoma.

7. The use according to claim 5, wherein APY29 is used for the preparation of a blocker of the invasion and migration of renal clear cell carcinoma.

8. A medicament for the treatment/prevention of a disease associated with RSK4 kinase, comprising said APY29.

9. The medicament of claim 8, wherein the medicament comprises sunitinib.

10. Use of a medicament according to claim 9 in the manufacture of a medicament for inhibiting abnormally active angiogenesis caused by renal clear cell carcinoma.